Biomedpharma Pharmaceutical Import Profile — Canada (DGFT 2022–2026)

Name: Biomedpharma Pharmaceutical Import Records from India — 2 Products, $1.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Biomedpharma — Pharmaceutical Importer Profile (2026) | 2 Products, $1.0M Trade | TransData Nexus

Biomedpharma

Pharmaceutical Importer · Canada · Cardiovascular Focus · $1.0M Total Trade · DGFT Verified

Biomedpharma is a pharmaceutical importer based in Canada with a total trade value of $1.0M across 2 products in 2 therapeutic categories. Based on 20 verified import shipments from Indian Customs (DGFT) records, Biomedpharma is the #1 buyer in 1 product including Calcium. Biomedpharma sources from 1 verified Indian supplier, with Intas Pharmaceuticals Limited accounting for 100.0% of imports.

Biomedpharma — Import Portfolio & Supplier Network

Biomedpharma import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Biomedpharma?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Intas Pharmaceuticals Limited	$1.2M	36	100.0%

Biomedpharma sources from 1 verified Indian supplier across 24 distinct formulations. The sourcing is highly concentrated — Intas Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Biomedpharma Import?

Formulation	Value	Ships
Pharma drugs and medi bio atorvastatin 20MG as per	$149.5K	3
Pharma drugs and medi bio atorvastatin 20MG as per	$101.0K	3
Pharma drugs and medi bio atorvastatin 40MG 500tbiomed#can as per	$100.0K	2
Ph.dru.& med.: bio atorvastatin 40MG tablets (atorvastatin calcium tablets 40MG)[1x500t per	$100.0K	2
Pharma drugs and medi pr bio-letrozole 2.5MG 3x10t ppbio-can as per	$71.4K	2
Pharma drugs and medi bio atorvastatin 80MG 100t as per	$59.0K	3
Pha.dru & medi, bio atorvastatin 10MG	$50.0K	1
Pha.dru & medi, bio atorvastatin 80MG	$50.0K	1
Pharma drugs and medi bio atorvastatin	$50.0K	1
Pharma drugs and medi bio atorvastatin 80MG 100tbiomed#can as per	$50.0K	1
Ph.dru.& med.: bio atorvastatin 80MG tablets (atorvastatin calcium tablets 80MG)[1x100t per	$50.0K	1
Ph.dru.& med.: bio atorvastatin 10MG tablets (atorvastatin calcium tablets 10MG)[1x500t per	$50.0K	1
Pharma drugs and medi pr	$49.2K	2
Pharma drugs and medi bio-montelukast	$46.4K	1
Phr drugs & medi fluoxetine BP 20MG	$40.9K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Atorvastatin	Cardiovascular	$800.0K	16	0.1%	2
2	Calcium	Vitamins & Supplements	$200.0K	4	0.0%	1

Biomedpharma imports 2 pharmaceutical products across 2 categories into Canada totaling $1.0M. The company is the #1 buyer for 1 product: Calcium.

Biomedpharma — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Biomed Pharma is a privately-owned Canadian pharmaceutical company headquartered in Montreal, Quebec. Established in 2002 as Biomed2002, the company initially focused on distributing generic drugs across Quebec. In 2014, it rebranded to Biomed Pharma to reflect its expanded vision and growth ambitions. By 2017, under new leadership, Biomed Pharma aimed to optimize its growth in the evolving pharmaceutical landscape by maintaining exceptional customer service and fostering innovation. (biomed-pharma.ca)

Biomed Pharma specializes in importing and marketing a diverse portfolio of pharmaceutical products, including high-volume generics, branded medications, biosimilars, and both prescription and over-the-counter natural health products. The company is committed to expanding its product range through strategic acquisitions and partnerships with global suppliers, ensuring the availability of high-quality products to meet the needs of the Canadian market. (biomed-pharma.ca)

2Distribution Network

Biomed Pharma's distribution network is centered in Quebec, with its headquarters located at 1B-9450, boulevard Langelier, Saint-Léonard, Quebec, Canada. The company serves pharmacies across Quebec, reflecting its regional focus. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, Biomed Pharma emphasizes a personalized approach to customer service, supported by a flexible administrative structure and a dynamic team. (biomed-pharma.ca)

3Industry Role

Biomed Pharma operates primarily as a pharmaceutical importer and distributor within Canada's supply chain. By importing a range of pharmaceutical products, including generics, branded medications, and biosimilars, the company plays a crucial role in ensuring the availability of diverse therapeutic options to meet the needs of Canadian healthcare providers and patients. (biomed-pharma.ca)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Biomedpharma

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Biomed Pharma's sourcing strategy exhibits a high degree of concentration, with all 20 shipments from India sourced exclusively from INTAS Pharmaceuticals Limited, amounting to a total import value of $1.0 million USD. This single-source dependency may present risks related to supply chain disruptions, such as production delays or regulatory changes affecting the supplier. However, the consistent sourcing from INTAS Pharmaceuticals Limited suggests a stable and reliable relationship, potentially mitigating some of these risks. The company's focus on a limited number of products—Atorvastatin and Calcium—further underscores this concentrated sourcing approach.

2Supply Chain Resilience

Biomed Pharma's supply chain resilience appears limited due to its exclusive reliance on INTAS Pharmaceuticals Limited for imports from India. The lack of backup suppliers and the narrow product range imported from India may expose the company to significant risks in the event of supply chain disruptions. Additionally, the absence of publicly available information regarding the regulatory compliance of INTAS Pharmaceuticals Limited and the diversity of shipping routes further highlights potential vulnerabilities in the supply chain.

3Strategic Implications

Importing Pharmaceuticals into Canada — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Canada

1Regulatory Authority & Framework

In Canada, the importation and sale of pharmaceutical products are regulated by Health Canada under the Food and Drugs Act and its associated Regulations. This framework ensures that all drugs, including prescription and over-the-counter medications, biologics, and natural health products, meet rigorous standards for safety, efficacy, and quality before they are authorized for sale in the Canadian market. (canada.ca)

2Import Licensing & GMP

To import pharmaceutical products into Canada, companies must obtain an Establishment Licence (EL) from Health Canada, authorizing them to import specific categories of drugs. Additionally, each drug product must have a Drug Identification Number (DIN) assigned by Health Canada, indicating that the product has been reviewed and authorized for sale in Canada. Importers are also required to ensure that their foreign manufacturing sites comply with Good Manufacturing Practice (GMP) standards recognized by Health Canada, such as those from the European Union (EU GMP), World Health Organization (WHO GMP), or Pharmaceutical Inspection Co-operation Scheme (PIC/S). (canada.ca)

3Quality & Labeling

Biomedpharma — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Biomed Pharma's focus on importing Atorvastatin and Calcium indicates a strategic emphasis on high-demand cardiovascular medications and essential supplements. The significant import value of Atorvastatin suggests a strong market demand for cholesterol-lowering therapies, while the importation of Calcium reflects a commitment to providing essential nutrients to the Canadian population. This product strategy aligns with the company's mission to offer a diversified portfolio of pharmaceutical products and services to meet the needs of healthcare professionals and patients. (biomed-pharma.ca)

2Sourcing Profile

Biomed Pharma's sourcing strategy is characterized by a focus on generic drugs, with a particular emphasis on formulations such as tablets, capsules, syrups, and injections. The company's exclusive reliance on INTAS Pharmaceuticals Limited for imports from India suggests a strategic choice to maintain a stable and reliable supply chain. However, this concentrated sourcing approach may limit the company's ability to diversify its product offerings and mitigate risks associated with supply chain disruptions.

3Market Positioning

Seller's Guide — How to Become a Supplier to Biomedpharma

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Biomed Pharma by offering a diversified range of pharmaceutical products that align with the company's focus on high-quality generics and essential medications. By meeting Health Canada's regulatory requirements and demonstrating compliance with recognized GMP standards, Indian exporters can position themselves as viable partners to support Biomed Pharma's mission to expand its product portfolio and address unmet needs in the Canadian market. (canada.ca)

2Requirements & Qualifications

Indian exporters seeking to supply Biomed Pharma must ensure that their products are authorized for sale in Canada, possessing a valid Drug Identification Number (DIN) issued by Health Canada. Manufacturing sites must comply with GMP standards recognized by Health Canada, such as EU GMP, WHO GMP, or PIC/S. Additionally, exporters must provide comprehensive product information, including monographs, labeling in both English and French, and evidence of compliance with Canadian regulatory requirements. (canada.ca)

3How to Approach

Frequently Asked Questions — Biomedpharma

What products does Biomedpharma import from India?

Biomedpharma imports 2 pharmaceutical products across 2 categories. Top imports: Atorvastatin ($800.0K), Calcium ($200.0K).

Who supplies pharmaceuticals to Biomedpharma from India?

Biomedpharma sources from 1 verified Indian suppliers. The primary supplier is Intas Pharmaceuticals Limited (100.0% of imports, $1.2M).

What is Biomedpharma's total pharmaceutical import value?

Biomedpharma's total pharmaceutical import value from India is $1.0M, based on 20 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Biomedpharma focus on?

Biomedpharma imports across 2 categories. The largest: Cardiovascular (80.0%), Vitamins & Supplements (20.0%).

Get Full Biomedpharma Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.